Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver Campus, 2405 Wesbrook Mall, Vancouver, BC, V6T 1Z3, Canada.
Department of Mathematics, Statistics, and Computer Science, University of Tehran, Tehran, Iran.
J Thromb Thrombolysis. 2024 Mar;57(3):437-444. doi: 10.1007/s11239-023-02921-8. Epub 2023 Dec 16.
Our objectives were to measure long-term adherence to oral anticoagulants (OACs) in patients with atrial fibrillation (AF) and to identify patient factors associated with adherence. Using linked, population-based administrative data from British Columbia, Canada, an incident cohort of adults prescribed OACs for AF was identified. We calculated the proportion of days covered (PDC) as a time-dependent covariate for each 90-day window from OAC initiation until the end of follow-up. Associations between patient attributes and adherence were assessed using generalized mixed effect linear regression models. 30,264 patients were included. Mean PDC was 0.69 (SD 0.28) over a median follow-up of 6.7 years. 54% of patients were non-adherent (PDC < 0.8). After controlling for confounders, factors positively associated with adherence were number of drug class switches, history of stroke or transient ischemic attack, history of vascular disease, time since initiation, and age. Age > 75 years at initiation, polypharmacy (among VKA users only), and receiving DOAC (vs. VKA) were negatively associated with adherence. PDC decreased over time for VKA users and increased for DOAC users. Over half of AF patients studied were, on average, nonadherent to OAC therapy and missed 32% of their doses. Several patient factors were associated with higher or lower adherence, and adherence to VKA declined during therapy while DOAC adherence increased slightly over time. To min im ize the risk stroke, adherence-supporting interventions are needed for all patients with AF, particularly those aged > 75 years, those with prior stroke or vascular disease, VKA users with polypharmacy, and DOAC recipients.
我们的目标是测量患有心房颤动(AF)的患者长期服用口服抗凝剂(OACs)的情况,并确定与依从性相关的患者因素。使用加拿大不列颠哥伦比亚省的链接、基于人群的行政数据,确定了一组新诊断为 AF 并接受 OAC 治疗的成年人队列。我们计算了每个 90 天窗口(从 OAC 开始到随访结束)的覆盖天数(PDC)作为时间依赖性协变量。使用广义混合效应线性回归模型评估了患者特征与依从性之间的关联。共纳入 30264 例患者。在中位随访 6.7 年期间,平均 PDC 为 0.69(SD 0.28)。54%的患者不依从(PDC<0.8)。在控制混杂因素后,与依从性呈正相关的因素包括药物种类的转换次数、中风或短暂性脑缺血发作史、血管疾病史、起始时间和年龄。起始年龄>75 岁、多药治疗(仅在 VKA 使用者中)和使用 DOAC(与 VKA 相比)与依从性呈负相关。VKA 使用者的 PDC 随时间降低,DOAC 使用者的 PDC 随时间增加。研究中的超过一半的 AF 患者平均不依从 OAC 治疗,漏服了 32%的剂量。几个患者因素与更高或更低的依从性相关,并且在治疗过程中 VKA 的依从性下降,而 DOAC 的依从性随着时间的推移略有增加。为了最大限度地降低中风风险,所有 AF 患者都需要进行依从性支持干预,尤其是年龄>75 岁的患者、有中风或血管疾病史的患者、有多种药物治疗的 VKA 使用者和 DOAC 使用者。